PharVision Advisers’s Autodesk ADSK Stock Holding History

PharVision Advisers’s Portfolio ADSK Stock Details ADSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-900	Closed	-$266K	–	105
2025 Q4	$266K	Buy	+900	New	+$272K	0.13%	349
2025 Q3	–	Sell	-1,377	Closed	-$426K	–	657
2025 Q2	$426K	Sell	1,377 -1,019	-43%	-$289K	0.61%	17
2025 Q1	$627K	Buy	2,396 +1,428	+148%	+$406K	0.87%	2
2024 Q4	$286K	Buy	+968	New	+$286K	0.24%	174

Other funds holding ADSK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

PharVision Advisers's ADSK Position: Q1 2026 in Review

PharVision Advisers sold out of Autodesk (ADSK) in Q1 2026, closing a stake of 900 shares — an estimated $266K sold.

PharVision Advisers first reported a position in ADSK in Q4 2024 and held it in 4 quarters. The position peaked at $627K in Q1 2025. 1,311 funds tracked by Wall St. Rank hold ADSK as of Q1 2026.

PharVision Advisers reported no remaining Autodesk position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 900 Autodesk shares in Q1 2026, an estimated $266K.
PharVision Advisers first reported a position in Autodesk in Q4 2024 and held it in 4 quarters.
PharVision Advisers's Autodesk position peaked at $627K in Q1 2025.
1,311 funds tracked by Wall St. Rank held Autodesk as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.